Azienda Sanitaria Universitaria Giuliano Isontina
- Address
- lock Available on a paid plan
Azienda Sanitaria Universitaria Giuliano Isontina - Comprehensive Clinical Research Center
Azienda Sanitaria Universitaria Giuliano Isontina is a distinguished medical research institution conducting cutting-edge clinical trials across diverse therapeutic areas. The center demonstrates particular expertise in hematologic malignancies, with extensive research programs in multiple myeloma, lymphomas, and leukemias, alongside significant contributions to cardiovascular and pulmonary disease research.
- Hematologic Oncology: Advanced trials in multiple myeloma, follicular lymphoma, Hodgkin's lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and immune thrombocytopenia with novel targeted therapies and immunotherapeutic approaches
- Cardiovascular Medicine: Pioneering research in cardiac amyloidosis, heart failure, hypertrophic cardiomyopathy, myocarditis, and pulmonary arterial hypertension utilizing innovative diagnostic and therapeutic strategies
- Rare Diseases and Precision Medicine: Specialized programs in transthyretin amyloidosis with cardiomyopathy, eosinophilic granulomatosis with polyangiitis, and myelodysplastic syndromes
- Pulmonary Research: Clinical investigations in chronic obstructive pulmonary disease, progressive pulmonary fibrosis, and advanced imaging studies in respiratory conditions
The center's research portfolio encompasses innovative approaches including CAR-T cell therapy, bispecific antibodies, and BTK inhibitors for hematologic conditions, while advancing non-invasive diagnostic imaging with PET-CT technology for cardiac amyloidosis. Additional research initiatives extend to solid tumors, including basal cell carcinoma, malignant melanoma, mesothelioma, and colorectal cancer, alongside studies in ophthalmologic conditions such as age-related macular degeneration and autoimmune glomerular diseases. The institution's commitment to precision medicine is evident through MRD-guided therapies and personalized treatment strategies across multiple disease states.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 12 therapeutic areas and 15 of 167 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 147 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 51 by active trials.
- 1Fondazione Italiana Linfomi Ets2active
lock +50 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Fondazione Italiana Linfomi Ets5trials
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Sanitaria Universitaria Giuliano Isontina
lock Showing 1 of 83 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multi-center, open-label, single-arm study to evaluate the efficacy and safety of oral rilzabrutinib in adults with immune thrombocytopenia (ITP) who failed first-line treatment | Sanofi-Aventis Recherche & Developpement | Phase III | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 167 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 10 | Unknown | 2019-09-27 | 2025-04-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.